Results 141 to 150 of about 8,656 (193)

From beta-cell failure to islet dysfunction: the emerging role of the alpha cell. [PDF]

BMJ Open Diabetes Res Care
Ramírez-Villegas NE, Martínez-Sánchez FD.   +1 more
europepmc   +1 more source

Combined Assessment of Gastrointestinal Hormones and Metabolomic Profiling Following Mixed-Meal Tolerance Tests in Patients at Increased Risk of Refeeding Syndrome: Study Protocol. [PDF]

J Pers Med
Nunes G, Guimarães M, Pereira SS, Mendes I, Vara-Luiz F, Oliveira C, Gonçalves M, Mendes P, Santos R, Meira T, Fonseca J.   +10 more
europepmc   +1 more source

Immune and Vascular Function in Cardiometabolic Disorders: Interplay With Sex Differences and Impact on Incretin Therapy. [PDF]

Acta Physiol (Oxf)
Muralikrishnan AS, Biasin V, Zabini D, Osto E.   +3 more
europepmc   +1 more source

Obstructive Sleep Apnea: An Evolving Therapeutic Landscape with an Emerging Role for Incretin-Based Therapies. [PDF]

Adv Ther
Xu B, Gaynor-Sodeifi K, Kundel V.
europepmc   +1 more source

Incretins and Lipid Metabolism

Current Medicinal Chemistry, 2018
Background: Recent findings indicate that incretin hormones and incretin-based therapies may affect the metabolism of lipoproteins, although the corresponding mechanisms are not clearly defined. Objective: To summarize the available data on the mechanisms linking incretins with the characteristics of serum lipoproteins and discuss the clinical ...
Moses Elisaf, Vasilis Tsimihodimos
exaly   +4 more sources

Incretins in the Therapy of Diabetic Kidney Disease

International Journal of Molecular Sciences, 2021
Diabetic kidney disease is a microvascular complication that occurs in patients with diabetes. It is strongly associated with increased risk of kidney replacement therapy and all-cause mortality.
Andrzej Pawlik, Weronika Bielka, Agnieszka Przezak   +2 more
exaly   +2 more sources

Possible Mechanisms and Molecular Signaling of Incretins against the Development of Type 2 Diabetes Mellitus

Current Molecular Pharmacology, 2023
The increasing number of cases of diabetes mellitus (DM) and related diseases has become a global health concern. In this context, controlling blood glucose levels is critical to prevent and/or slow down the development of diabetes-related complications.
Zatollah Asemi, Omid Vakili, Alireza Mafi   +2 more
exaly   +2 more sources

The physiology and pharmacology of incretins in type 2 diabetes mellitus

Diabetes, Obesity and Metabolism, 2008
Udgivelsesdato: 2008/8Two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide (GLP)-1, help control blood glucose levels by affecting plasma insulin levels in response to oral glucose intake - this is known as ...
Jens Juul Holst
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Incretins

Journal of Intensive Care Medicine, 2015
Glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are the known incretin hormones in humans, released predominantly from the enteroendocrine K and L cells within the gut. Their secretion is regulated by a complex of integrated mechanisms involving direct contact for the activation of different chemo-sensors on the ...
Tongzhi, Wu, Christopher K, Rayner, Michael, Horowitz   +2 more
openaire   +4 more sources

Small intestinal physiology relevant to bariatric and metabolic endoscopic therapies: Incretins, bile acid signaling, and gut microbiome

Techniques and Innovations in Gastrointestinal Endoscopy, 2020
Incretins, bile acids and the gut microbiome are involved in the pathophysiology of obesity and type 2 diabetes. The incretins glucagon-like peptide-1 and glucose-dependent-insulinetrophic polypeptide, both influence beta-cell function, insulin and ...
Max Nieuwdorp, Donald L van der Peet
exaly   +2 more sources